JP2011505835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505835A5 JP2011505835A5 JP2010538155A JP2010538155A JP2011505835A5 JP 2011505835 A5 JP2011505835 A5 JP 2011505835A5 JP 2010538155 A JP2010538155 A JP 2010538155A JP 2010538155 A JP2010538155 A JP 2010538155A JP 2011505835 A5 JP2011505835 A5 JP 2011505835A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- sequence
- nucleic acid
- site
- retroviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 15
- 230000001177 retroviral effect Effects 0.000 claims 15
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000002950 deficient Effects 0.000 claims 10
- 230000010354 integration Effects 0.000 claims 10
- 239000002773 nucleotide Substances 0.000 claims 10
- 125000003729 nucleotide group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 230000006798 recombination Effects 0.000 claims 9
- 238000005215 recombination Methods 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 238000004806 packaging method and process Methods 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 230000010076 replication Effects 0.000 claims 6
- 241001430294 unidentified retrovirus Species 0.000 claims 6
- 230000026683 transduction Effects 0.000 claims 5
- 238000010361 transduction Methods 0.000 claims 5
- 238000012546 transfer Methods 0.000 claims 5
- 102000018120 Recombinases Human genes 0.000 claims 3
- 108010091086 Recombinases Proteins 0.000 claims 3
- 102000008579 Transposases Human genes 0.000 claims 3
- 108010020764 Transposases Proteins 0.000 claims 3
- 230000002463 transducing effect Effects 0.000 claims 3
- 108010077544 Chromatin Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000003483 chromatin Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 230000007067 DNA methylation Effects 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 240000007019 Oxalis corniculata Species 0.000 claims 1
- 108091027981 Response element Proteins 0.000 claims 1
- 241001492360 Retroviral provirus Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004025 env Genes Proteins 0.000 claims 1
- 101150030339 env gene Proteins 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000012856 packing Methods 0.000 claims 1
- 230000001124 posttranscriptional effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US711807P | 2007-12-11 | 2007-12-11 | |
| US61/007,118 | 2007-12-11 | ||
| PCT/US2008/086409 WO2009076524A2 (en) | 2007-12-11 | 2008-12-11 | Polypurine tract modified retroviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013974A Division JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011505835A JP2011505835A (ja) | 2011-03-03 |
| JP2011505835A5 true JP2011505835A5 (https=) | 2012-02-02 |
| JP5749014B2 JP5749014B2 (ja) | 2015-07-15 |
Family
ID=40756119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538155A Expired - Fee Related JP5749014B2 (ja) | 2007-12-11 | 2008-12-11 | ポリプリントラクト改変レトロウイルスベクター |
| JP2015013974A Expired - Fee Related JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015013974A Expired - Fee Related JP6001702B2 (ja) | 2007-12-11 | 2015-01-28 | ポリプリントラクト改変レトロウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9796987B2 (https=) |
| EP (2) | EP3342872A1 (https=) |
| JP (2) | JP5749014B2 (https=) |
| CY (1) | CY1119905T1 (https=) |
| DK (1) | DK2222861T3 (https=) |
| ES (1) | ES2664988T3 (https=) |
| HR (1) | HRP20180184T1 (https=) |
| HU (1) | HUE036103T2 (https=) |
| LT (1) | LT2222861T (https=) |
| NO (1) | NO2222861T3 (https=) |
| PL (1) | PL2222861T3 (https=) |
| PT (1) | PT2222861T (https=) |
| RS (1) | RS56844B1 (https=) |
| SI (1) | SI2222861T1 (https=) |
| TR (1) | TR201802323T4 (https=) |
| WO (1) | WO2009076524A2 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| US8329162B2 (en) | 2006-07-21 | 2012-12-11 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
| RS53257B2 (sr) * | 2009-07-24 | 2018-06-29 | Immune Design Corp | Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa |
| WO2012112691A1 (en) | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| WO2013149167A1 (en) | 2012-03-30 | 2013-10-03 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| ES2738582T3 (es) | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| KR101607282B1 (ko) | 2014-12-18 | 2016-03-29 | 충남대학교산학협력단 | 유리형 산화환원조절단백-1 및 이를 함유하는 항염증 약학조성물 |
| WO2016118780A1 (en) | 2015-01-21 | 2016-07-28 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| WO2017083291A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| AU2016354102B2 (en) | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| JP2019509275A (ja) | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| MA45783A (fr) | 2016-07-29 | 2019-06-05 | Juno Therapeutics Inc | Procédés d'évaluation de la présence ou de l'absence d'un virus compétent pour la réplication |
| KR20190098747A (ko) | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| SG11202000606TA (en) | 2017-07-29 | 2020-02-27 | Juno Therapeutics Inc | Reagents for expanding cells expressing recombinant receptors |
| KR20250016455A (ko) | 2017-08-09 | 2025-02-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법 |
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| EP3704229B1 (en) | 2017-11-01 | 2023-12-20 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| US12258580B2 (en) | 2017-11-01 | 2025-03-25 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| MX2020005907A (es) | 2017-12-08 | 2020-10-19 | Juno Therapeutics Inc | Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma. |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| JP2021511802A (ja) | 2018-01-31 | 2021-05-13 | ジュノー セラピューティクス インコーポレイテッド | 複製可能ウイルスの存在または非存在を評価するための方法および試薬 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3853247A2 (en) | 2018-09-19 | 2021-07-28 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
| MA54078A (fr) | 2018-11-01 | 2021-09-15 | Juno Therapeutics Inc | Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| IL283218B2 (en) | 2018-11-16 | 2025-11-01 | Juno Therapeutics Inc | Dosing methods of engineered T cells for the treatment of malignant B cells |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| PT3886875T (pt) | 2018-11-30 | 2024-06-27 | Juno Therapeutics Inc | Métodos para tratamento utilizando terapia celular adotiva |
| CN113692285A (zh) | 2018-11-30 | 2021-11-23 | 朱诺治疗学股份有限公司 | 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法 |
| MX2021012607A (es) | 2019-04-17 | 2022-03-11 | Alpine Immune Sciences Inc | Metodos y usos de proteinas de fusion de ligando icos (icosl) variante. |
| CN114207136A (zh) | 2019-06-07 | 2022-03-18 | 朱诺治疗学股份有限公司 | 自动化t细胞培养 |
| KR20220034782A (ko) | 2019-06-12 | 2022-03-18 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법 |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| JP2022554348A (ja) | 2019-11-05 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | 治療用ｔ細胞組成物の属性を決定する方法 |
| MX2022006715A (es) | 2019-12-06 | 2022-09-23 | Juno Therapeutics Inc | Metodos relacionados con toxicidad y respuesta asociada con terapia celular para tratar neoplasias malignas de celulas b. |
| EP4093433A1 (en) | 2020-01-24 | 2022-11-30 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| JP2023512209A (ja) | 2020-01-28 | 2023-03-24 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞形質導入のための方法 |
| JP2023522857A (ja) | 2020-04-10 | 2023-06-01 | ジュノー セラピューティクス インコーポレイテッド | Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用 |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| KR20230024283A (ko) | 2020-05-13 | 2023-02-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도 |
| CA3197730A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffman-La Roche Ag | Nucleic acid constructs for va rna transcription |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| CN117321200A (zh) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | 评估病毒载体颗粒效力的方法 |
| AU2022241654A1 (en) | 2021-03-22 | 2023-09-28 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
| CN117858719A (zh) | 2021-03-29 | 2024-04-09 | 朱诺治疗学股份有限公司 | 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法 |
| US20240279310A1 (en) | 2021-05-07 | 2024-08-22 | Alpine Immune Sciences, Inc. | Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein |
| WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
| KR20240137075A (ko) | 2022-01-28 | 2024-09-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 조성물의 제조 방법 |
| WO2023172883A1 (en) | 2022-03-07 | 2023-09-14 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| KR20250099778A (ko) | 2022-10-04 | 2025-07-02 | 알파인 이뮨 사이언시즈, 인코포레이티드 | 자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질 |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| KR20260026101A (ko) | 2023-05-23 | 2026-02-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법 |
| WO2024263991A2 (en) * | 2023-06-22 | 2024-12-26 | Arc Research Institute | Methods and compositions for integration deficient viral vectors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861161A (en) | 1994-09-07 | 1999-01-19 | Universite De Montreal | Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions |
| JP2000503527A (ja) * | 1995-11-28 | 2000-03-28 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 条件付き複製ウイルスベクターおよびその用途 |
| WO2001030965A2 (en) | 1999-10-28 | 2001-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of in vivo gene transfer using a sleeping beauty transposon system |
| US6673567B2 (en) | 2000-03-23 | 2004-01-06 | E. I. Du Pont De Nemours And Company | Method of determination of gene function |
| US20030003565A1 (en) * | 2000-11-27 | 2003-01-02 | Dubensky Thomas W. | Functional lentiviral vector from an MLV-based backbone |
| EP1534847B1 (en) | 2002-09-03 | 2015-10-28 | Oxford Biomedica (UK) Limited | Retroviral vector and stable packaging cell lines |
| US7220578B2 (en) * | 2002-11-27 | 2007-05-22 | Tal Kafri | Single LTR lentivirus vector |
| EP2055316A1 (en) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Lentivirus vector-based approaches for generating an immune response to HIV in humans |
| GB0325379D0 (en) * | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| US20060019393A1 (en) * | 2003-12-04 | 2006-01-26 | Cannon Paula M | Minimal lentiviral vector system |
| US20070048285A1 (en) * | 2005-08-24 | 2007-03-01 | Christopher Baum | Self-inactivating retroviral vector |
| EP1757703A3 (en) | 2005-08-24 | 2007-12-05 | Medizinische Hochschule Hannover | Self-inactivating retroviral vector |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
-
2008
- 2008-12-11 PL PL08859393T patent/PL2222861T3/pl unknown
- 2008-12-11 US US12/747,076 patent/US9796987B2/en active Active
- 2008-12-11 EP EP17204678.1A patent/EP3342872A1/en not_active Withdrawn
- 2008-12-11 JP JP2010538155A patent/JP5749014B2/ja not_active Expired - Fee Related
- 2008-12-11 TR TR2018/02323T patent/TR201802323T4/tr unknown
- 2008-12-11 WO PCT/US2008/086409 patent/WO2009076524A2/en not_active Ceased
- 2008-12-11 HU HUE08859393A patent/HUE036103T2/hu unknown
- 2008-12-11 SI SI200831929T patent/SI2222861T1/en unknown
- 2008-12-11 HR HRP20180184TT patent/HRP20180184T1/hr unknown
- 2008-12-11 DK DK08859393.4T patent/DK2222861T3/en active
- 2008-12-11 LT LTEP08859393.4T patent/LT2222861T/lt unknown
- 2008-12-11 RS RS20180107A patent/RS56844B1/sr unknown
- 2008-12-11 ES ES08859393.4T patent/ES2664988T3/es active Active
- 2008-12-11 PT PT88593934T patent/PT2222861T/pt unknown
- 2008-12-11 NO NO08859393A patent/NO2222861T3/no unknown
- 2008-12-11 EP EP08859393.4A patent/EP2222861B1/en active Active
-
2015
- 2015-01-28 JP JP2015013974A patent/JP6001702B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-23 US US15/790,530 patent/US10017785B2/en active Active
-
2018
- 2018-02-09 CY CY20181100167T patent/CY1119905T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011505835A5 (https=) | ||
| US8828718B2 (en) | Gene transfer vectors comprising genetic insulator elements and methods to identify genetic insulator elements | |
| Park | Lentiviral vectors: are they the future of animal transgenesis? | |
| Delenda | Lentiviral vectors: optimization of packaging, transduction and gene expression | |
| KR102091957B1 (ko) | 레트로바이러스 생산을 위한 안정한 세포주 | |
| JP6001702B2 (ja) | ポリプリントラクト改変レトロウイルスベクター | |
| Wiznerowicz et al. | Harnessing HIV for therapy, basic research and biotechnology | |
| Chang et al. | The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors | |
| CN105705645B (zh) | 逆转录病毒载体 | |
| Pluta et al. | Use of HIV as a gene transfer vector | |
| US20170145438A1 (en) | Viral Vectors for Gene Editing | |
| Hauber et al. | Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice | |
| CN113302291B (zh) | 使用逆转录病毒整合酶-Cas9融合蛋白通过定向非同源DNA插入进行的基因组编辑 | |
| JP2006524051A (ja) | 両方向性合成プロモーターを備えたレンチウイルスベクターおよびその使用 | |
| JP6878620B2 (ja) | レトロウイルス産生のための安定な細胞株 | |
| WO2004056966A2 (en) | Methods of inhibiting gene expression by rna interference | |
| Lois et al. | Retroviruses as tools to study the immune system | |
| JP2023024951A (ja) | ヘアピンループ末端自己相補的二本鎖共有結合閉鎖直鎖状ｄｎａベクター、製造システムおよびプロセス、ならびに得られた前記ｄｎａベクターの使用 | |
| Dehdilani et al. | Genetically engineered birds; pre-CRISPR and CRISPR era | |
| CN116867901A (zh) | 功能性核酸分子和方法 | |
| Everson et al. | Retroviral vector interactions with hematopoietic cells | |
| Goyvaerts et al. | Targeted lentiviral vectors: current applications and future potential | |
| Fang et al. | Application advances of lentiviral vectors: From gene therapy to vaccine development | |
| CN105274089B (zh) | 一种表达绿色荧光囊膜融合蛋白的rev病毒传染性克隆的构建方法 | |
| RU2013115637A (ru) | Усовершенствование генетических конструкций для повышения эффективности антивич терапии |